Get in Touch

With Winston SHIM

Name and email
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Associate Professor

Winston SHIM

Associate Professor
Graduate Diploma in Financial Management , Singapore Institute of Management, Singapore
Cluster:
Health and Social Sciences
Email

SIT Appointments

  • Associate Professor
    – Present
  • Assistant Professor
    –

Education

  • Graduate Diploma in Financial Management
    Singapore Institute of Management , Singapore
  • Doctor of Philosophy in Molecular and Cellular Biology
    National University of Singapore , Singapore
  • Bachelor of Science with Honours in Biotechnology
    Murdoch University , Australia

Achievements

  • European Society of Cardiology Traveling Fellowship
  • NMRC Glaxo Wellcome Cardiology Traveling Fellowship
  • Best Publication Award, National Heart Centre
  • Young Investigator Award (2nd Prize), the 16th Singapore Cardiac Society Annual Scientific Meeting
  • 2003 Best Poster Award (2nd prize), the 14th Singapore General Hospital Annual Scientific Meeting

Professional Memberships

  • Member, Working group on Myocardial Function, European Society of Cardiology
    – Present
  • Member, Working group on Cellular Biology of the Heart, European Society of Cardiology
    – Present
  • Member, Working group on Atherosclerosis and Vascular Biology, European Society of Cardiology
    – Present
  • Member, Cardiovascular Scientific Committee, International Society for Cellular Therapy
    –

Corporate Experience

  • Co-Founder, Web Biotechnology Pte Ltd
    Present
  • 2008- Co-Founder/Chief Scientific Officer, Innoheart Pte Ltd
    Present
  • Duke-NUS: Associate Professor, Cardiovascular and Metabolic Disorders Program
    –
  • Duke-NUS: Assistant Professor, Cardiovascular and Metabolic Disorders Program
    –
chevron--up

Current Projects

  • Cellular and Large Animal Modeling of Heart Failure with Preserved Ejection Fraction
    – Present

    This study focuses on disease modeling to understand heart failure with preserved ejection fraction and cardiac dysfunction via mechanical and biochemical investigation and large animal modeling to comprehensively represent whole spectrum of disease manifestation.

  • Study of hypertrophic cardiomyopathy and heart failure using induced pluripotent stem cells
    – Present

    This study focuses on disease modeling to understand left ventricular hypertrohpy and cardiac dysfunction via mechanical, electrical and biochemical investigation and large animal modeling to comprehensively represent whole spectrum of disease manifestation.

Past Projects

  • Study of intracellular signaling of developmental biology and cellular maturation of human cardiomyocytes
    –

    This study focuses on understanding signaling transduction pathways involving ErbB receptor family that linking p38 MAPK and Stat3 in cell fate determination, cardiac differentiation and cellular maturation via molecular and biochemical analysis.

  • Characterization of relationship of calcium-handling in cardiac arrhythmia and cardiac ageing
    –

    This study focuses on understanding interplay of calcium regulation in electromechanical transduction and cardiac arrhythmia via cardiac electrophysiology, microelectrode array and calcium transients/calcium sparks.

chevron--up

Journal Papers

  • Ramanchandra CJA, Ja KPMM, Chua J, Cong S, Shim W, Hausenloy DJ. Myeoloperoxidase as a multifacted target for cardiovascular protection. Antioxid Redox Signal 2020;32:1135-49.

  • Ramachandra CJA, Chua J, Cong S, KP JMM, Shim W, Wu JC, Hausenloy DJ. Human induced pluripotent stem cells for modeling metabolic perturbations and impaired bioenergetics uderlying cardiomyopathies. Cardiovasc Res 2020;DOI:10.1093/cvr/cvaa125.

  • Ong SB, Kwek XY, Katwadi K, Hernandez-Resendiz S, Crespo-Avilan GE, Ismail NI, Lin YH, Yap EP, Lim SY, Ja KPMM, Ramachandra CJA, Tee N, Toh JJ, Shim W, Wong P, Cabrera-Fuentes HA, Hausenloy DJ. Targeting mitochondrial fission using Mdivi-1 in a clinically relevant large animal model of acute myocardial infarction: a pilot study. Int J Mol Sci 2019;DOI:10.3390/ijms20163972.

  • Ramachandra CJA, Mai Ja KPM, Lin YH, Shim W, Boisvert WA, Hausenloy DJ. Induced pluripotent stem cells for modeling energetic alterations in hypertrophic cardiomyopathy. Cond Med 2019;2:142-51.

  • Viswanathan SK, Puckelwartz MJ, Mehta A, Ramachandra CJA, Jagadeesan A, Fritsche-Danielson R, Bhat RV, Wong P, Kandoi S, Schwanekamp JA, Kuffel G, Pesce LL, Zilliox MJ, Durai UNB, Verma RS, Molokie RE, Suresh DP, Khoury PR, Thomas A, Sanagala T, Tang HC, Becker RC, Knöll R, Shim W, McNally EM, Sadayappan S. Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3Δ25bpIntronic Deletion in South Asian Descendants. JAMA Cardiol. 2018 Jun 1;3(6):481-488.

  • Myu Mai Ja KP, Lim KP, Chen A, Ting S, Li SQ, Tee N, Ramachandra C, Mehta A, Wong P, Oh S, Shim W. Construction of a vascularized hydrogel for cardiac tissue formation in a porcine model. J Tissue Eng Regen Med. 2018 Apr;12(4):e2029-e2038.

  • Ramachandra CJA, Mehta A, Wong P, Ja KPMM, Fritsche-Danielson R, Bhat RV, Hausenloy DJ, Kovalik JP, Shim W. Fatty acid metabolism driven mitochondrial bioenergetics promotes advanced developmental phenotypes in human induced pluripotent stem cell derived cardiomyocytes. Int J Cardiol. 2018 Dec 1;272:288-297

  • Ho IAW, Shim WSN. Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity. Biomed Res Int. 2017;2017:9634172.

  • A Mehta, CJA Ramachandra, P Singh, Anuja Chitre, CG Lua, M Mura, L Crotti, P Wong, PJ Schwartz, M Gnecchi, W Shim. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur Heart J. 2018 Apr 21;39(16):1446-1455.

  • A Mehta, CJA Ramachandra, A Chitre, P Singh, CH Lua, W Shim. Acetylated STAT3 functions as molecular adaptor independent of transcriptional activity during human cardiogenesis. Stem Cells. 2017 Oct;35(10):2129-2137.

  • M Mura, A Mehta, C Ramachandra, F Pisano, MC Ciuffreda, M Boni, L Crotti, P Schwartz, W Shim, M Gnecchi. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. Int J Cardiol. 2017; 240:367-371.

  • Ramachandra C, Mehta A, Wong P and Shim W. ErbB4 Activated p38ã MAPK isoform Mediates Early Cardiogenesis through NKx2.5 in Human Pluripotent Stem Cells. Stem Cells. 2016; 34(2):288-98.

  • Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouladi MA, Ghosh S, Shim W, Brunham LR. Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell-derived cardiomyocytes. Sci Rep. 2016; 6:25333. Doi:10.1038/srep25333.

  • Ramachandra C, Mehta A, Lua CH, Chitre A, Ja KP and Shim W. ErbB receptor tyrosine kinase: A molecular switch between cardiac and neuroectoderm specification in human pluripotent stem cells. Stem Cells. 2016; 34(10):2461-70.

  • Ma D, Wei H, Lu J, Huang D, Liu Z, Loh LJ, Islam O, Liew R, Shim W, Cook SA. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes.Stem Cell Res Ther. 2015 Mar 19;6:39.

  • Ramachandra CJ, Mehta A, Guo KW, Wong P, Tan JL, Shim W. Molecular pathogenesis of Marfan syndrome. Int J Cardiol. 2015;187:585-91.

  • A Mehta, G Sequiera, C Ramachandra, Y Sudibyo, P Yong, CH Koh, W Shim. Phasic Modulation of Wnt Signaling Enhances Cardiac Differentiation in Human Pluripotent Stem Cells by Recapitulating Developmental Ontogeny. Biochim Biophys Acta. 2014; 1843(11):2394-2402.

  • A Mehta, G Sequiera, Y Sudibyo, C Ramachandra, YY Chung, JW Sheng, KY Wong, TH Tan, P Wong, R Liew, W Shim. Re-Trafficking of hERG Reverses Long QT Syndrome 2 Phenotype in Human iPS-derived Cardiomyocytes. Cardiovascular Research. 2014; 102(3):497-506.

  • A Mehta, G Sequiera, YY Chung, W Shim. Pharmaco-Electrophysiology of Viral-free Induced Pluripotent Stem Cell-derived Human Cardiomyocytes. Toxicology Sciences 2013; 131(2):458-69.

  • A Mehta, YY Chung, A Ng, F Iskandar, S Atan, HM Wei, W Sun, G Dusting, P Wong, W Shim. Pharmacological Response of Human Cardiomyocytes Derived from Viral-free Induced Pluripotent Stem Cell. Cardiovascular Research. 2011; 91(4):577-586.

Conferences

  • Characterization of heart failure with preserved ejection fraction in a porcine model. Heart Failure Congress 2017. Paris, France.

  • Single nucleotide polymorphisms discriminates between symptomatic and asymptomatic LQTS2 patients: A DNA-based patient classification. European Society of Cardiology Congress 2015. London, United Kingdom.

  • Allelic variations in hERG expression discriminates between symptomatic and asymptomatic LQTS2 patient-hiPSC derived cardiomyocytes. European Society of Cardiology Congress 2014. Barcelona, Spain.

  • Human mesenchymal stem cells improve regional contractility of infarcted myocardium by echocardiographic speckle imaging. World Conference on Regenerative Medicine 2013. Leipzig, Germany.

  • Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human pluripotent stem cell-derived cardiomyocytes. European Society of Cardiology Congress 2013. Amsterdam, The Netherlands.

  • Proarrhythmogenic and repolarization risk stratification using viral-free human induced pluripotent stem cell derived cardiomyocytes. International Society for Stem Cell Research Annual Meeting 2012. Yokohama, Japan.

  • Pharmaco-electrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. Joint Cold Spring Harbor Asia/SSCR Conference on Cellular Programs and Reprogramming 2011. Suzhou, China.

  • Dynamics of active and passive contribution of stem cell scaffolding in cardiomyoplasty for post myocardial infarction. European Society of Cardiology Congress 2011. Paris, France.

chevron--up